Shikari® (S-ATE) Anti-Etanercept ELISA
ETA-QLS-ENB
Enzyme immunoassay for the qualitative determination of antibodies to etanercept in serum and plasma.
This kit has been especially developed for the qualitative antibodies to etanercept in serum and plasma samples
Etanercept (Enbrel®) was associated to the development of anti-etanercept antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Enbrel®. This might lead to severe complications. This Kit can be efficiently used for monitoring anti-etanercept antibodies during therapy and offers the clinician a tool for decision on possible preventive measures such as possible addition of immunosuppressive drug to reduce anti-etanercept antibodies.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system and have CE IVD mark.
For technical inquiry, please contact techsupport@matriksbiotek.com
| Required Volume (µl) | 20 |
| Total Time (min) | 140 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | - |
| Spike Recovery (%) | +/- |
| Shelf Life (year) | 1 |
| Assay type | Qualitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
| # | File | Action |
|---|---|---|
| Instructions For Use | Download | |
| Safety Data Sheet (SDS) | Download |
Publications with this drug
| # | File | Action |
|---|---|---|
| Iwasaki, Takeshi, et al. "Dynamics of type I and type II interferon signature determines responsiveness to anti-TNF therapy in rheumatoid arthritis." Frontiers in immunology 13 (2022). | Visit Link | |
| MOHSEN, ENAS RIYADH, and NAAEL H. ALI. "IMPACT OF TH17/TREGFOXP3 CELLS RATIO ON RHEUMATOID ARTHRITIS PATIENTS RECEIVING ANTI TNF-THERAPY-." Journal of Duhok University 24.2 (2021): 90-102.APA | Visit Link | |
| Lombardi S, Bernardoni C, Bertolucci D, et al. Biologic therapies in rheumatic diseases: drug and anti-drug antibody levels and clinical efficacy. Journal of Autoimmunity and Cell Responses, 4(1), 2017. | Visit Link | |
| Aldrich MB, Velasquez FC, Kwon S, Lymphatic delivery of etanercept via nanotopography improves response to collagen-induced arthritis, et al., Arthritis Research & Therapy 19:116, 2017. | Visit Link | |
| Gibellini L, De Biasi S, Bianchini E, et al. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis. Richard Y, ed. PLoS ONE. 11(12), 2016 | Visit Link | |
| Erdemli Ö, et al, In vitro evaluation of effects of sustained anti-TNF release from MPEG-PCL-MPEG and PCL microspheres on human rheumatoid arthritis synoviocytes.2014. Journal of Biomaterials Application, 29(4):524-42, 2014. | Visit Link | |
| Jung Y et al., “Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis”, J. Control. Release 2013. | Visit Link | |
| Cheong C, et al, Etanercept Attenuates Traumatic Brain Injury in Rats by Reducing Brain TNF-α Contents and by Stimulating Newly Formed Neurogenesis, Mediators of Inflammation, 2013; Volume 2013, Article ID 620837, 9 pages ** | Visit Link | |
| TNF-α antagonist attenuates systemic lipopolysaccharide-induced brain white matter injury in neonatal rats Shin, Seung Han, M.D. | Visit Link | |
| CONTROLED DRUG DELIVERY SYSTEMS FOR ANTI-TNF-α Aysen TEZCANER Dilek Keskin Seza OZEN Bulent ATILLA Ali USANMAZ Cetin KOCAEFE Ozge ERDEMLI | Visit Link |
